Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. announced the election of Dr. Yang Jin as an Independent Non-executive Director, effective September 29, 2025. This change also affects the composition of the Remuneration and Appraisal Committee and the Nomination Committee, with Dr. Yang Jin and Ms. Lu Kun taking new roles. The abolishment of the Board of Supervisors marks a significant shift in the company’s governance structure, potentially impacting its operational and strategic direction.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on the development and commercialization of innovative therapies, particularly in the field of immunotherapy.
Average Trading Volume: 13,139,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.